Journal Article10.1016/J.CANLET.2004.06.014
Cyclooxygenases in cancer: progress and perspective.
407
TL;DR: The rapid development of safe and effective inhibitors targeting individual COX enzymes not only dramatically improved the understanding of the function of COX-2, but also resulted in discovery ofCOX independent functions of NSAIDs, providing important hints for future drug design.
read more
About: This article is published in Cancer Letters. The article was published on 08 Nov 2004. The article focuses on the topics: Mouse model of colorectal and intestinal cancer & Cancer.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Symmetrical and un-symmetrical curcumin analogues as selective COX-1 and COX-2 inhibitor.
TL;DR: It is reported here that most of the curcumin analogues display selective inhibition ofCOX-2, whereas a few suppress COX-1 activity, and that the compound with pronounced selectivity for COx-2 displayed better binding to COZ-2 compared toCurcumin.
Cyclooxygenase-2 is involved in S100A2-mediated tumor suppression in squamous cell carcinoma.
TL;DR: Findings first showed a potent antitumor role of S100A2 in squamous cell carcinoma partly via reduced expression of COX-2, frequently overexpressed in various types of cancer and plays an important role in tumor progression.
New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines.
Nicolas Beziere,Laurence Goossens,Jean Pommery,Hervé Vezin,Nadia Touati,Jean-Pierre Hénichart,Nicole Pommery +6 more
TL;DR: The design of profen hybrids containing a NO donor moiety connected to an aliphatic spacer led to compounds with a similar cyclooxygenase inhibition compared to their parent profen and with significant antiproliferative activities on PC3 cells.
Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance.
Brigitte M.T. Hougardy,John H. Maduro,Ate G.J. van der Zee,Pax H.B. Willemse,Steven de Jong,Elisabeth G.E. de Vries +5 more
TL;DR: An overview of the molecular options that can change the apoptotic balance in cervical cancer, through increasing death-receptor-mediated apoptosis, the use of proteasome inhibitors, short interfering RNAs, or non-steroidal anti-inflammatory drugs (NSAIDs) is presented.
Houttuynia cordata, a novel and selective COX-2 inhibitor with anti-inflammatory activity.
TL;DR: The data suggest HC mediates inhibition of COX-2 enzyme activity and can affect related gene and protein expression and work by a mechanism of action similar to that of NSAIDs.
References
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
TL;DR: Experiments with guinea-pig lung suggest that some of the therapeutic effects of sodium salicylate and aspirin-like drugs are due to inhibition of the synthesis of prostaglandins.
8.8K
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
TL;DR: Important insights into the mechanisms of inflammatory responses, pain, and fever have been gleaned from the current understanding of eicosanoid biology.
3.8K
Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation
TL;DR: Leukotrienes C4, D4, and E4, which are released from the lung tissue of asthmatic subjects exposed to specific allergens, seem to play a pathophysiological role in immediate hypersensitivity reactions.
2.8K
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
Charles E. Eberhart,Robert J. Coffey,Aramandla Radhika,Francis M. Giardiello,Suzanne Ferrenbach,Raymond N. DuBois +5 more
TL;DR: COX-2, but not COX-1, gene expression is markedly elevated in most human colorectal cancers compared with accompanying normal mucosa, and COx-2 expression seems to be increased in a subset of adenomas.
2.6K
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Gideon Steinbach,Patrick M. Lynch,R. K. S. Phillips,Marina Wallace,Ernest T. Hawk,Gary Gordon,Naoki Wakabayashi,Brian D. Saunders,Yu Shen,Takashi Fujimura,Li Kuo Su,Bernard Levin,Louis Godio,Sherri Patterson,Miguel A. Rodriguez-Bigas,Susan L. Jester,Karen L. King,Marta Schumacher,James L. Abbruzzese,Raymond N. DuBois,Walter N. Hittelman,Stuart O. Zimmerman,Jeffrey W. Sherman,Gary J. Kelloff +23 more
TL;DR: In patients with familial adenomatous polyposis, six months of twice-daily treatment with 400 mg of celecoxib, a cyclooxygenase-2 inhibitor, leads to a significant reduction in the number of colorectal polyps.
2.6K